Protocol Ledger

NCT03993379 · Phase II · TERMINATED

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Interventional Phase II clinical trial protocol NCT03993379 sponsored by CytomX Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-20 Enrollment: 3 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03993379
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03993379
Protocol FieldVerified Registry Value
NCT IdentifierNCT03993379
Consolidated Lead SponsorCytomX Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment3 participants (ACTUAL)
Registered Start Date2019-11-20
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI